Avalo Therapeutics (AVTX) Accumulated Expenses (2014 - 2026)

Avalo Therapeutics' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $11.2 million for Q1 2026.

• Quarterly Accumulated Expenses rose 145.8% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (up 145.8% YoY) and the FY2025 annual result came in at $12.8 million, up 102.68% from the prior year.
• Accumulated Expenses was $11.2 million for Q1 2026 at Avalo Therapeutics, down from $12.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $14.1 million in Q1 2022 and bottomed at $4.2 million in Q4 2023.
• A 5-year average of $8.9 million and a median of $7.6 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses sank 68.43% — and 2026, when it surged 145.8%.
• Avalo Therapeutics' Accumulated Expenses stood at $13.2 million in 2022, then sank by 68.43% to $4.2 million in 2023, then jumped by 51.41% to $6.3 million in 2024, then jumped by 102.68% to $12.8 million in 2025, then declined by 12.18% to $11.2 million in 2026.
• Business Quant data shows AVTX's Accumulated Expenses at $11.2 million in Q1 2026, $12.8 million in Q4 2025, and $7.5 million in Q3 2025.